Powering Precision
Powering Precision
Learn about our expanding body of data in lung, melanoma and GI malignancies to be presented at the 2023 ASCO Congress on June 3-6, 2023.
Signatera™ Residual Disease test is the first and only commercially available personalized ctDNA assay, widely validated across solid tumors to help answer important clinical questions along the entire continuum of care.
Learn about our expanding body of data in lung, melanoma, and GI malignancies
We are presenting important new data at the 2023 ASCO Annual Meeting, demonstrating the clinical utility and performance of Signatera™ Residual Disease (MRD) test for patients with various solid tumor types.
June 2, 2023
-
Molecular Residual Disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized Soft Tissue Sarcoma (STS)
Oral Presentation: SarcomaOral Presentation (Clin Sci Symposium S404)
June 3, 2023
-
Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma
Esophageal - Poster presentation -
Association of Tumor- Informed Minimal Residual Disease (MRD) with Clinical Outcomes for Muscle Invasive Bladder Cancer (MIBC) – A Multicenter Retrospective Real World Analysis
MIBC - Poster Presentation -
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma
Melanoma - Poster Presentation
June 4, 2023
-
Circulating Tumor DNA (ctDNA) Monitoring Informs Maintenance Outcomes in Patients (pts) with Advanced NSCLC Treated with Induction Atezolizumab+Carboplatin+Nab-Paclitaxel (A+CnP)
Lung - Poster Presentation -
””Lung
-
Utilization of Circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors
Thymus - Poster Presentation
June 5, 2023
-
Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response
Esophageal - Poster Presentation -
Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer
CRC - Oral Presentation(Clinical Science Symposium Hall D2) -
Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy: sub-analysis of the randomized phase 2 STAMP trial
Bile - Poster Presentation
-
Circulating Tumor DNA and Association with CAR-T Cell Therapy Response in Gastric and Pancreatic Cancer Patient
Pancreatic - Poster Presentation -
Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan
CRC - Poster Discussion Presentation -
Positive ctDNA-based Minimal Residual Disease Assays During Surveillance Are Associated with High Rates of Undiagnosed Concomitant Radiographic Recurrences in Colorectal Cancer (CRC) - Results from the MD Anderson INTERCEPT Program
CRC - Poster Discussion Presentation
Trevor
Living with colorectal cancer
Natera’s Oncology Portfolio
A single tissue source upfront provides a comprehensive genomic profile
Learn about Signatera for your clinical trial
Well-designed and successful clinical trials help facilitate earlier “go/no go” decision-making. A trial with Signatera can ultimately enhance the R&D pipeline productivity and impact label expansion of approved oncology drugs to new treatment settings.
Why Partner with us?
-
Experienced team with Global reach: CE Mark, three FDA Breakthrough Device Designations, 8 Non-Significant Risk (NSR) determinations
-
>60 Natera IP assets covering ctDNA MRD and monitoring
-
Clinically validated across multiple solid tumors, Signatera has shown to predict relapse in >98% of patients without further treatment*